Protagenic lands $1.5M to fund first US anxiety drug trial
What's the deal? Protagenic TherapeuticsDealroom has a profile for this one. Try Dealroom → has raised $1.5 million in upfront gross proceeds through a private placement with new and existing investors. The clinical-stage biopharmaceutical company, which develops peptide-based therapies for stress-related neuropsychiatric disorders, could receive up to $3.5 million more if two series of milestone-linked warrants are exercised in full, bringing total potential proceeds to $5 million before fees.
Where the money goes: Protagenic plans to complete IND-enabling work for its lead asset, PT00114, and launch a Phase 1/2a trial in generalized anxiety disorder (GAD). Brookline Capital MarketsDealroom has a profile for this one. Try Dealroom →, a division of Arcadia Securities, is sole placement agent.
Why now? In August 2026, the US Food and Drug Administration (FDA) responded to Protagenic's pre-IND meeting request and identified no deficiencies that would block an IND submission. The company has since finalized its study design and is targeting an IND filing by year-end, with first patient dosing in the second quarter of 2027.
What's the endgame? PT00114 is a first-in-class investigational neuropeptide, a synthetic analog of a brain peptide thought to regulate the body's stress response. The Phase 1/2a trial will test safety, tolerability, and pharmacokinetics across ascending-dose cohorts, then evaluate a GAD patient cohort for early efficacy signals. It would be the drug's first US study.
The program builds on two Phase 1 studies completed outside the US. In the most recent multiple ascending dose study, which reported positive topline safety results in December 2025, PT00114 was well tolerated across all dose levels, with no serious adverse events.
What could go wrong? The round is constrained. The "up to" $5 million is a ceiling, not cash in hand, and the extra $3.5 million depends on warrant exercises. Protagenic is pre-revenue, was delisted from Nasdaq in January, and faces a $250,000 note due at an equity raise or within 180 days. The US trial would advance development, not establish efficacy.
"We expect this financing to take us into the clinic and to the enrollment of our first patients, which we believe will be a value inflection point for the Company," said Bill Nichols Jr., president of Protagenic. He added that the company continues to pursue "additional capital" to resource its priority research.
The signal: For a small, cash-tight company, this is a bridge to the clinic rather than a decisive war chest. Topline safety data is expected in the second half of 2027 and exploratory efficacy data in the first half of 2028 — the milestones that will determine whether Protagenic can raise more on better terms.
Read more: streetinsider.com
Image credit: Generated with Gemini